| Literature DB >> 27920092 |
Winfried Randerath1,2,3, Johan Verbraecken4,2,3, Stefan Andreas5,6, Michael Arzt7, Konrad E Bloch8, Thomas Brack9, Bertien Buyse10, Wilfried De Backer4, Danny Joel Eckert11, Ludger Grote12, Lars Hagmeyer13, Jan Hedner12, Poul Jennum14, Maria Teresa La Rovere15, Carla Miltz13, Walter T McNicholas16, Josep Montserrat17, Matthew Naughton18, Jean-Louis Pepin19, Dirk Pevernagie20, Bernd Sanner21, Dries Testelmans21, Thomy Tonia22, Bart Vrijsen10, Peter Wijkstra23, Patrick Levy19,3.
Abstract
The complexity of central breathing disturbances during sleep has become increasingly obvious. They present as central sleep apnoeas (CSAs) and hypopnoeas, periodic breathing with apnoeas, or irregular breathing in patients with cardiovascular, other internal or neurological disorders, and can emerge under positive airway pressure treatment or opioid use, or at high altitude. As yet, there is insufficient knowledge on the clinical features, pathophysiological background and consecutive algorithms for stepped-care treatment. Most recently, it has been discussed intensively if CSA in heart failure is a "marker" of disease severity or a "mediator" of disease progression, and if and which type of positive airway pressure therapy is indicated. In addition, disturbances of respiratory drive or the translation of central impulses may result in hypoventilation, associated with cerebral or neuromuscular diseases, or severe diseases of lung or thorax. These statements report the results of an European Respiratory Society Task Force addressing actual diagnostic and therapeutic standards. The statements are based on a systematic review of the literature and a systematic two-step decision process. Although the Task Force does not make recommendations, it describes its current practice of treatment of CSA in heart failure and hypoventilation.Entities:
Mesh:
Substances:
Year: 2017 PMID: 27920092 DOI: 10.1183/13993003.00959-2016
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671